Read about the latest breakthroughs, awards and ongoing work from the SGC. Discover how our work is making a global impact and driving forward the field of drug discovery. Interested in getting first the latest news from SGC?
The Structural Genomics Consortium (SGC) recently launched a new scientific public-private partnership in tuberculosis and malaria drug discovery: the Structure-guided Drug Discovery Coalition, SDDC. Participants to the Coalition include the Seattle Structural Genomics Center for…
Laminopathies are a group of rare genetic disorders caused by mutations in genes encoding proteins involved in the building and maintenance of the nuclei of cells. Severe laminopathies such as the premature ageing syndrome pregeria leads to death in the teens from heart disease and other symtoms…
GlaxoSmithKline has developed a potent, selective, cell-active EZH2 inhibitor, GSK343, and has made this available as a chemical probe as part of the SGC epigenetics initiative. The histone H3-lysine 27 (H3K27) methyltransferase EZH2 plays a critical role in regulating gene expression, and…
Categories